The annual Enforcement, Litigation, and Compliance Conference brings together industry, regulators, attorneys, litigators, academics, and consultants to discuss trends and issues in enforcement and compliance, the latest developments in both civil and criminal litigation, and recent cases and settlements. This conference offers an opportunity to hear from and interact with top officials from FDA, DOJ, FTC, and other government agencies. 

Attendees will:

  • Explore the latest trends behind enforcement actions in food, drugs, biologics, medical devices, and tobacco
  • Gain practical tips and best practices for responding to enforcement action by FDA or other government agencies
  • Learn how to comply with new and upcoming FDA rules and regulations
  • Hear directly from FDA’s Center Compliance Directors on top issues, priorities, and goals for 2018

Diamond Sponsor

Diamond Sponsor

Gold Sponsor

Silver Sponsor

Silver Sponsor

Silver Sponsor

Silver Sponsor

Silver Sponsor

Bronze Sponsor

Bronze Sponsor

Call for Proposals

FDLI and the Conference Planning Committee thanks those who participated in the Call for Proposals this summer. The input received from industry stakeholders helps us plan a timely program. If you submitted a proposal, you will be notified of the acceptance status of your proposal in September.

Register by October 20 and SAVE!

Industry & Firms

$1,099
  • +$100 for nonmembers
  • +$100 after 10/20/2017
  • +$100 after 11/9/2017

Non-Profit

$799
  • +$100 for nonmembers
  • +$100 after 10/20/2017
  • +$100 after 11/9/2017

Government

$799
  • +$100 for nonmembers
  • +$100 after 10/20/2017
  • +$100 after 11/9/2017

Academic

$799
  • +$100 for nonmembers
  • +$100 after 10/20/2017
  • +$100 after 11/9/2017

Student

$99
  • +$100 for nonmembers
  • +must provide transcripts
  • +must be full-time student

Agenda

subject to change

Wednesday, December 6

8:00–8:45 AM                
Registration and Continental Breakfast

8:45–8:50 AM
Welcome and Opening Remarks
Amy Comstock Rick, President & CEO, Food and Drug Law Institute

8:50–9:20 AM                 
Ethan Davis, Deputy Assistant Attorney General, Consumer Protection Branch, US Department of Justice

9:20–10:20 AM              
Compliance Central with FDA Center Compliance Directors: Part I
This two-part session will address FDA’s top compliance issues, enforcement priorities, and goals for 2018. Hear directly from each FDA Center Compliance Director, learn how industry should focus their compliance efforts, and what really happens when you don’t follow FDA regulations.

Donald Ashley, Director, Office of Compliance, Center for Drug Evaluation and Research, FDA (Invited)
Sean Boyd, Deputy Director for Regulatory Affairs, Office of Compliance, Center for Devices and Radiological Health, FDA
Mary Malarkey, Director, Office of Compliance and Biologics Quality, Center for Biologics Evaluation and Research, FDA (Invited)

10:20–10:40 AM            
Coffee and Networking Break                                            

10:40–11:40 AM            
Compliance Central with FDA Center Compliance Directors: Part II

Daniel McChesney, Director, Office of Surveillance and Compliance, Center for Veterinary Medicine, FDA (Invited)
William Correll, Director, Office of Compliance, Center for Food Safety and Nutrition, FDA (Invited)
Ann Simoneau, Director, Office of Compliance and Enforcement, Center for Tobacco Products, FDA (Invited)

11:40–12:30 PM            
Concurrent Breakout Sessions: How FDA’s Program Alignment Affects Your Industry
Why is the Program Alignment good for industry, and what are the challenges? What will be the impact on inspections, both domestic and foreign? During these breakout sessions, you will learn about the implications of FDA’s recent Program Alignment. Speakers will discuss what the new offices are, how program alignment will affect changes on the ground, and whether there have been any gaps or unintended consequences.

  1. Medical Products
  2. Foods
  3. Tobacco

12:30–1:45 PM              
Networking Luncheon with Roundtable Discussions

1:45–2:45 PM                 
Concurrent Breakout Sessions in Your Industry

  1. Drug/Device: BIMO
    Each year, FDA publishes its BioResearch Monitoring (BIMO) inspection metrics that cover all the medical product centers at FDA. Violations included failure to have or follow investigational plans or continuing reviews, deviation from protocol, and inadequate records. These types of violations can easily be avoided with a strong Human Research Protection Program (HRPP). A good HRPP must be designed to support all those involved in the research endeavor through proper staffing and procedures, training and education, and monitoring and oversight. We will explore the regulatory requirements generally, what the common regulatory pitfalls are in this space, and how to design and manage an HRPP to avoid a problematic BIMO inspection. 
  2. FSMA Enforcement: The First Year
    Now that the first compliance dates for FSMA regulations have passed, the focus has shifted from preparation to implementation. What should you expect, and how can you prepare? What are both companies and inspectors seeing thus far? This session will feature first-hand accounts from attorneys on the FSMA “front lines,” and will include lessons learned so far from FDA enforcement.
  3. Tobacco: ENDS
    How FDA is enforcing against current active regulatory requirements (such as age restrictions) for websites, online marketplaces, and social media platforms? During this session, we will delve into FDA’s current enforcement and strategy around this area and understand how other companies within the space are combating these types of sales.

 2:45–3:00 PM                 
Coffee and Networking Break   

 3:00–3:55 PM                 
Concurrent Breakout Sessions

  1. Drugs: Quality Systems Approach to Data Integrity
    This panel will delve into data integrity issues, including how to address data integrity problems and what the agency expects. Speakers will also analyze FDA’s “new” data integrity warning letter language and the expectations it creates for manufacturers, including how to respond.
  2. Medical Devices: Do I need to Open a CAPA?
    There is widespread disagreement in industry about when to open a Corrective and Preventive Action (CAPA). When is it appropriate to open a CAPA, and what are the implications of doing so, or choosing not to? What are agency expectations – should everything go into a CAPA? If not, how are non-CAPA activities managed, and where are they documented? What will FDA expect to see during an inspection? What role have CAPAs played in medical device litigation?
  3. FDA Regulation, Competitor Actions, and Private Litigation:
    In the food industry, labels and label claims have garnered enforcement actions from FDA, other government agencies, competitors, and private litigants based. A company could find itself in the midst of all of the above, based on a single claim on one product. What are key techniques to avoid prevent or minimize risk of an enforcement action by a government agency – FDA or otherwise – and subsequent action by a private actor? What can other industries learn from what has happened in the food industry?

4:00–5:00 PM                 
Enforcement Throughout the Supply Chain
As companies continue to shift manufacturing operations and procurement overseas, knowing your supply chain and having comprehensive quality agreements becomes increasingly important. In addition, there are substantive differences between foreign inspections and domestic inspections, in terms of notice and agency responsibility, and more subtle differences, in terms of cultural differences, language barriers, and actions that FDA has viewed as delaying, denying, limiting, or refusing an inspection, which can lead to enforcement actions. This session will discuss how to succeed in foreign inspections, what your responsibilities are, and ensuring your supply chain is secure.

5:00–7:00 PM                 
FDLI 2017 Annual Holiday Reception

 

Thursday, December 7

8:30–8:55 AM                
Registration and Continental Breakfast

8:55–9:00 AM                 
FDLI Welcome and Remarks

Laura Brown, Director, Educational Programs, FDLI

9:00–9:45 AM                
Keynote Address

9:45–10:45 AM              
Recent Trends in Criminal Enforcement
This session will provide an overview of recent criminal cases, and current priorities for OCI and DOJ with respect to criminal prosecutions.  In addition, panelists will discuss how to avoid criminal prosecution, and best practices for responding if you or your firm is the target of a criminal investigation.

10:45–11:00 AM            
Coffee and Networking Break

11:00–12:00 PM            
Management Oversight and Control: How to Ensure Compliance and Limit Liability
FDA expects senior management to exercise appropriate oversight and control of manufacturing operations to ensure product quality and public safety.  Panelist will discuss management responsibility and communications related to establishment inspections, recalls, warning letters and government enforcement.  The panel will also discuss how communications on these topics have the potential to trigger shareholder derivative suits or product liability, and how to mitigate these risks.  

12:05–1:00 PM              
Concurrent Breakout Sessions

  1. ORA and CDER: A New Concept of Operations (ConOps)
    The Center for Drug Evaluation and Research (CDER) and the Office of Regulatory Affairs (ORA) have entered into an unprecedented concept of operations (ConOps) agreement to integrate facility evaluations and inspections for human drugs. The agreement, Integration of FDA Facility Evaluation and Inspection Program for Human Drugs: A Concept of Operations, outlines the responsibilities and the workflow for Pre-Approval, Post-Approval, Surveillance, and For-Cause Inspections at domestic and international facilities. This panel will discuss the improvements in communications and processes between ORA and CDER, and consider the impacts on industry.
  2. Medical Devices: Cybersecurity, IoT, and FDA
  3. First Amendment Issues in Advertising and Product Packaging

1:00–2:00 PM                 
Luncheon Address: Fifth Annual Eric M. Blumberg Memorial Lecture

2:00 PM                           
Conference Adjournment

 

 

 

 

Planning Committee

Committee Chair

Cathy Burgess, Partner, Alston & Bird LLP

Committee Members

Deborah M. Autor, SVP/Head of Strategic Global Quality & Regulatory Policy, Mylan Pharmaceuticals, Inc.
David J. Bloch, Principal Legal Counsel, Corporate Legal Regulatory, Medtronic
John C. Garvey, Principal / Chief Executive Officer, Compliance Architects LLC
George M. Karavetsos, Partner, DLA Piper LLP
Peter J. Leininger, Counsel, King & Spalding LLP
Bob Rhoades, Managing Partner, Validant
Marta L. Villarraga, Principal, Exponent, Inc.
Anne K. Walsh, Director, Hyman, Phelps & McNamara, PC
Jessica Zeller, ORA Ombudsman, FDA

Continuing Legal Education

FDLI applies for CLE credits in Ohio, Pennsylvania, and Virginia. These CLE approvals may also be honored by other states; please check with your bar association for guidance. The CLE credits will be posted as they are granted and you can request to be notified when approval is received.

Location and Overnight Accommodations

Location

Capital Hilton
1001 16th St NW
Washington, DC 20036

Overnight Accommodations

Rooms are available at a discounted rate of $269 a night through November 14 at the Capital Hilton Hotel.

Driving, Parking, and Public Transportation

Capital Hilton Hotel is a short walk from the McPherson Square and Farragut North Metro stations. Valet parking is available for $59 each day. Parking garages are also available nearby.

Please contact the Conference Department with any accessibility requirements or dietary restrictions, or for other questions.